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Abstract
Background: Melioidosis is a disease caused by Burkholderia pseudomallei and considered endemic in South-East
Asia but remains poorly documented in Cambodia. We report the first series of hospitalized pulmonary melioidosis
cases identified in Cambodia describing clinical characteristics and outcomes.
Methods: We characterized cases of acute lower respiratory infections (ALRI) that were identified through
surveillance in two provincial hospitals. Severity was defined by systolic blood pressure, cardiac frequency,
respiratory rate, oxygen saturation and body temperature. B. pseudomallei was detected in sputum or blood
cultures and confirmed by API20NE gallery. We followed up these cases between 6 months and 2 years after
hospital discharge to assess the cost-of-illness and long-term outcome.
Results: During April 2007 - January 2010, 39 ALRI cases had melioidosis, of which three aged ≤2 years; the
median age was 46 years and 56.4% were males. A close contact with soil and water was identified in 30 patients
(76.9%). Pneumonia was the main radiological feature (82.3%). Eleven patients were severe cases. Twenty-four
(61.5%) patients died including 13 who died within 61 days after discharge. Of the deceased, 23 did not receive
any antibiotics effective against B. pseudomallei. Effective drugs that were available did not include ceftazidime.
Mean total illness-related costs was of US$65 (range $25-$5000). Almost two-thirds (61.5%) incurred debt and 28.2%
sold land or other belongings to pay illness-related costs.
Conclusions: The observed high fatality rate is likely explained by the lack or limited access to efficient antibiotics
and under-recognition of the disease among clinicians, which led to inappropriate therapy.
Keywords: Burkholderia pseudomallei community-acquired pneumonia, tuberculosis, Cambodia
Background
Melioidosis is an infectious disease due to non-sapro-
phytic Gram-negative bacillus Burkholderia pseudomal-
lei, which can be found in wet soil and surface water
[1]. Endemic areas encompass Southeast Asia and
Northern Australia demonstrating seasonality with more
cases detected/reported during the rainy season [2,3]. In
addition to contact with an environmental exposure,
underlying conditions pre-disposing for the disease
include diabetes mellitus, alcohol abuse, chronic lung
disease and chronic renal disease [1,4]. The three main
routes of contamination are cutaneous inoculation,
inhalation and ingestion [5]. Presentation of the disease
is highly variable ranging from acute septicemia to
chronic localized abscess while most infections with B.
pseudomallei are asymptomatic [6]. Lungs are the most
commonly infected organs but every organ may be
affected. Other frequent localizations include skin
abscess, osteomyelitis, arthritis, prostatic and parotids
abscesses [1,7,8]. Diagnosis of melioidosis relies on the
isolation of B. pseudomallei in clinical samples (mostly
blood, sputum and pus). Serology is useful for epidemio-
logical surveys but of little diagnostic interest since most
of the population is sero-positive in endemic areas [9].
Analysis of resistance patterns of the B. pseudomallei
strains showed that severe cases of melioidosis were
best treated with at least 10 days of intravenous
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weeks of an oral eradication therapy using a three-drug
regimen (i.e. trimethoprim-sulfamethoxazole and doxy-
cycline) [5,10]. Outcome depends on both severity of
cases and the level of health services. Septicemia and
acute pulmonary forms are the most severe with fatality
rates as high as 40%, despite appropriate treatment [1].
Melioidosis remains poorly documented in many
countries of the endemic areas [4]. This applies to Cam-
bodia where first indigenous cases were recently
reported [11-13]. A study in Siem Reap province
reported the detection of antibodies against B. pseudo-
mallei in 16% of Cambodian children and isolation in
30% of the surrounding rice fields, which indicates high
exposure to the pathogen [14].
This report summarizes the characteristics of pulmon-
ary melioidosis cases among patients hospitalized with
acute lower respiratory infection and the results of a fol-
low-up investigation of these cases several months after
hospital discharge.
Methods
In April 2007, we implemented surveillance of acute
lower respiratory infections (ALRI) in two Cambodian
provincial hospitals (Takeo, Southern province and
Kampong Cham, Eastern province) combined with iden-
tification of bacterial and viral etiologies. Four adult
(Internal Medicine, Infectious Disease, Intensive Care)
and two Pediatric wards participated in the surveillance
study. Eligibility criteria for ALRI included symptoms
onset ≤14 days, fever ≥ 38°C or a history of febrile epi-
sodes within the previous 3 days, recent cough, plus at
least one of the following respiratory symptoms: dys-
pnea, chest pain or crackles on lung auscultation.
Patients with known tuberculosis (TB), or known
acquired immunodeficiency such as HIV, chronic corti-
costeroids use and cancer were excluded.
For each participant, hospital clinicians were asked to
complete a standardized surveillance form, including
information on patient’s medical history, clinical fea-
tures, treatment, laboratory and radiological findings
and patients’ outcome at discharge. A chest X-ray was
requested for each enrolled patient within 24 hours
from admission; blood tests (i.e. complete blood cells
count, glycemia, liver enzymes, blood creatinine levels
and serum electrolytes) and sputum smear microscopy
for acid-fast bacilli detection were performed on site.
The surveillance forms and chest X-rays were retrospec-
tively reviewed by an expert pulmonologist.
Blood and sputum were sent daily to the Institut Pas-
teur - Cambodia (IPC) for culture and antibiotic suscept-
ibility testing (AST). B. pseudomallei was cultured from
sputum on Drigalski and Ashdown’sa g a ra n di d e n t i f i e d
by API20NE gallery (BioMérieux). Blood sample was
taken on Hemoline Diphasic Performance bottle (Bio-
Mérieux) for adults and Isolator 1.5 (Oxoid) (1.5 ml) for
children. We determined antimicrobial drug susceptibil-
ity by the disk-diffusion method on Mueller-Hinton agar
plates (Bio-Rad). When B. pseudomallei appeared resis-
tant to cotrimoxazole, Minimum inhibitory concentra-
tions were determined using the E-test diffusion method
(AB Biodisk) to confirm or infirm resistance [1]. Bacter-
iology results were returned to the patient’s clinicians as
soon as they were available, together with AST.
The follow-up investigation
For the purpose of the study, we visited and interviewed
all confirmed melioidosis cases at home within six
months after hospital discharge to assess the patient’s
status and collect additional information using a stan-
dardized questionnaire. We collected information
regarding known risk factors for melioidosis (i.e. pre-
vious pulmonary disease or history of smoking, diabetes
mellitus, chronic disease, alcohol intake, repeated con-
tact with wet soils), medical history of infection, wounds
or abscesses, time to diagnosis, disease evolution, date
of death if appropriate, and economic burden on
patients’ families. Patients were visited a second time
between 6 months and 2 years after the first home visit
to follow-up on possible relapse.
Definitions
A pulmonary melioidosis case was defined as a patient
with a febrile illness and respiratory symptoms with the
identification of B. pseudomallei in sputum and/or blood
culture. A severe case was defined by the presence of at
least two of the following criteria: systolic blood pressure
<90 mmHg, cardiac frequency ≥120 beats-per-minute,
respiratory rate ≥30/mn, oxygen saturation <90%, tem-
perature <35°C or ≥40°C. For children, severity was
assessed using the World Health Organization criteria
[15]. In the present study, we defined chronic forms of
melioidosis when re-assessment (follow-up investigation)
of patient’s medical history revealed onset of symptoms
>14 days. Since no patient was taking anti-diabetic drug,
we retained as diabetic every patient with glycemia >126
mg/dL or a history of diabetes mellitus. Chronic lung dis-
ease includes chronic bronchitis and pre-existing pul-
monary lesions. Renal impairment was defined by serum
creatinine levels > 2 mg/dL. A necrotizing pneumonia
was defined by the presence of radiographic imaging of
either cavity or abscess, unique or multiple.
Treatment
Antibiotics that are effective against B. pseudomallei and
available in Takeo and Kampong Cham include sulfa-
methoxazol-trimethoprime (cotrimoxazole), chloram-
phenicol, doxycycline, co-amoxiclav. The standard
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weeks of a four-antibiotic regimen including cotrimoxa-
zole, chloramphenicol and doxycycline. If the patient’s
condition had significantly improved on week 8 of treat-
ment, chloramphenicol would be discontinued [1]. An
out-patient follow-up was implemented at each hospital
during and after the treatment.
Ethics
The surveillance study was approved by the Cambodian
National Ethical Committee. All patients/parents of sick
children who participated in surveillance provided writ-
ten informed consent.
Statistical methods
Statistical analyses were performed using Stata version
9.0 (Statacorp, College Station, TX, USA). Continuous
variables were presented with their median (minimum
and maximum ranges) or with their mean and standard
deviation. Variables were compared across groups using
the Wilcoxon-Mann-Whitney test for continuous vari-
ables, and the Chi-square or Fisher’s exact test for cate-
gorical variables. For all analyses, statistical significance
was defined as P < 0.05.
Results
Patients’ characteristics
From April 2007 to February 2010, 2,840 patients with
ALRI (i.e. pneumonia, abscess, pleural effusion,
superinfection on lung sequelae, bronchitis) were
reported through surveillance and 2,407 had at least one
sample available (1,985 in Takeo and 422 in Kampong
Cham) for bacteriological testing. Among these patients
with ALRI, 39 (1.6%) were confirmed as having been
infected by B. pseudomallei, of which 35 were treated at
Takeo and 4 at Kampong Cham hospital; the proportion
of B. pseudomallei isolates among positive cultures was
9.3% including 51.4% in blood culture and 7.7% in spu-
tum culture. The demographics and baseline character-
istics of patients are presented in Table 1. The median
age on admission was 46 years (range 1 month - 74
years). Among the 39 patients, 3 were children of which
one was less than two months old. Two adults had a
history of near-drowning. Underlying conditions identi-
fied as a risk factor were reported in 23 (59.0%) patients
(Table 1). Among these 23 patients, 7 had diabetes mel-
litus and one tested positive for HIV antibodies. A soil
exposure or close contact with water was identified in
30 (76.9%) patients. All of them reported working in
rice fields and some reported additional activities such
as fishing, collecting water plants or working in con-
struction. One patient was pregnant, but her pregnancy
term could not be ascertained.
Clinical and microbiological diagnosis
Of the reported cases, 15 were confirmed by sputum
culture, 18 by blood culture and 6 by both. In-depth
interviews during the follow-up investigation actually
Table 1 General characteristics of the 39 melioidosis cases
All patients
(n = 39)
Non severe
(n = 28)
Severe
(n = 11)
P value
Male 22 (56.4%) 19 (67.9%) 3 (27.3%) 0.03
Age, median years (min. - max.) 46 (0.08-74) 47.5 (19-72) 29 (0.08-74)
Risk factors
Close contact with wet soil 30 (76.9%) 23 (82.1%) 7 (63.6%)
Underlying chronic disease 23 (59.0%) 21 (75.0%) 2 (18.2%) <0.01
Diabetes mellitus 7 (18.0%) 7 (25.0%)
Renal impairment 4 (10.3%) 3 (10.7%) 1 (9.1%)
Chronic lung disease 13 (33.3%) 12 (42.6%) 1 (9.1%)
Alcoholism 12 (30.8%) 10 (35.7%) 2 (22.2%)
Data on admission
Temperature ≥ 38°C 27 (69.2%) 17 (60.7%) 10 (90.9%)
Cough 38 (97.4%) 27 (96.4%) 11 (100%)
Dyspnea 30 (76.9%) 21 (75.0%) 9 (81.8%)
Thoracic pain 31 (79.5%) 26 (92.9%) 5 (45.5%) <0.01
Hemoptysis 1 (2.6%) 1 (3.7%)
Leucocytes median 10
3/mm
3 9.4 (6.5-14.4) 10.9 (7.6-16.6) 6.4 (3.2-9.4) <0.01
Pneumonia 27/34 (79.4) 20/27 (74.0) 7/7 (100)
Pleural effusion 2/28 (7.1%) 2/27 (7.4%)
Outcome
Death 24/39 (61.5%) 13/15 (46.4%) 11/11 (100) <0.01
Time to death, days (min-max) 3 (1-61) 3 (1-61) 3 (1-14)
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beyond 14 days (median 30 days, range 21 days - 3
years); onset of symptoms could not be ascertained for
four patients. Eleven (28.2%) patients including all
pediatric cases were severe. None of the two patients
with history of near drowning was severe on admission.
Twenty-eight (71.8%) were identified during the rainy
season (from May to October). Detailed clinical and
laboratory data are presented in Table 1. Productive
cough was present in 28 (71.8%) cases. One patient had
hemoptysis without cavity on chest radiography. Leuco-
cytes count was significantly higher in acute melioidosis
(14.3% vs. 8.5%; p < 0.01) and in non-severe cases
(10.9% vs. 6.4%; p < 0.01). Liver enzymes level did not
significantly differ between severe/non-severe cases or
acute/chronic forms.
A positive blood culture was significantly associated
with severe cases (10/11 vs. 14/26; p = 0.03). Although
5/7 (71.4%) diabetic patients had positive blood culture,
none was severe. No patient had bacterial co-infection;
however, two of the 3 children had H3N2 influenza A
virus infection. Bacteriological results and B. pseudomal-
lei sensitivity to main antibiotics are displayed in Tables
2 and 3. All the strains were susceptible to cotrimoxa-
zole with E-test method, although 20 (51.3%) were not
susceptible with disk-diffusion method.
Radiological features
Chest radiographs were only available in 34 (87.2%)
cases (Table 4). Of these, 5 patients had no evidence of
pneumonia or pleural effusion, 2 only had pleural effu-
sions and 27 (79.4%) had pneumonia associated with
abscesses, nodules or pleural effusions; 16 (59.3%) pneu-
monia consisted of pulmonary lesions in two or more
lobes. All severe melioidosis cases for which chest radio-
graphs were available showed evidence of pneumonia
with either alveolar consolidation (n = 2), nodules (n =
3) or pleuropneumonia (n = 2). Two patients who had
normal chest radiographs tested positive for B.
pseudomallei by blood culture. Pulmonary sequelae
were found on 3 chest radiographs including emphy-
sema, probable TB sequelae and bronchiectasis related-
post-infection. Interestingly the experts panel inter-
preted chest radiographs of five cases of melioidosis as
TB-like (Figure 1); all but one were negative for acid-
fast bacilli (AFB) by direct sputum examination (in line
with the national TB program, AFB negative pneumo-
nias evocative of TB are not systematically cultured).
Three of these five cases had chronic melioidosis.
Treatment and outcome
Only 13 patients (none were severe) received antibiotics
active against B. pseudomallei either during hospitaliza-
tion or after discharge. The mean duration of hospitali-
sation was 6 days (range 1 - 11 days) with a shorter
duration for severe patients (2 days [1-4] vs 8 [2-12];
Table 2 Types of bacteriological results from melioidosis
cases
All
patients
(n = 39)
Non
severe
(n = 28)
Severe
(n = 11)
P
value
Source of isolates
Sputum 21/22
(95.5%)
19/20
(95.0%)
2/2 (100%)
Blood culture 24/37
(64.9%)
14/26
(53.8%)
10/11
(90.9%)
0.03
Sputum and blood
culture
6 (15.4%) 5 (17.9%) 1 (9.1%)
Resistant strains to
co-amoxiclav
5 (13.5%) 3 (11.5%) 2 (18.2%)
Table 3 In vitro activities of selected antibiotics against
39 strains of B. pseudomallei
Agent Sensitive Intermediate Resistant
Amoxicillin-clavulanate 32 (82.1%) 2 (5.1%) 5 (12.8%)
Aztreonam 29 (74.4%) 10 (25.6%)
Ceftazidime 39 (100%)
Chloramphenicol 38 (97.4%) 1 (2.6%)
Cotrimoxazole* 39 (100%)
Imipenem 39 (100%)
Piperacillin 39 (100%) 1 (2.6%)
Piperacillin-tazobactam 39 (100%) 1 (2.6%)
Tetracyclin 38 (94.8%) 1 (2.6%)
Ticarcillin 4 (10.3%) 35 (89.7%)
Ticarcillin-clavulanate 12 (30.8%) 15 (38.4%) 12 (30.8%)
*Susceptibility testing was done by diffusion disk method for all antibiotics. E-
test method was only used to detect resistance to cotrimoxazole
Table 4 Radiographic features on acute and and chronic
melioidosis cases’ chest X-rays
All
patients
(n = 34*)
Patients with
acute
melioidosis
(n = 19)
Patients with
chronic
melioidosis
(n = 13)
Pneumonia** 27
(79.4%)
13 (68.4%) 12 (92.3%)
Necrotizing 10
(29.4%)
6 (31.6%) 4 (30.8%)
Nodular 5 (17.9%) 1 (5.3%) 2 (15.4%)
With pleural effusion 4 (11.8%) 1 (5.3%) 3 (23.1%)
Pleural effusion 2 (5.9%) 1 (5.3%) 1 (7.7%)
No pneumonia or
pleural effusion
5 (14.7%) 5 (26.3%)
Pulmonary sequelae 3 (8.8%) 3 (15.8%)
Normal X-ray 2 (5.9%) 2 (5.9%)
* 5/39 patients did not have an X-ray of which 4 were severe on admission;
onset of symptoms could not be documented in 2/34 patients, ** P > 0.05
between acute and chronic melioidosis
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45.8% (11/24) died during admission. Among the
deceased, 23 (96%) patients died without having received
any of the active drugs (i.e. cotrimoxazole, chloramphe-
nicol, doxycycline, amoxicillin-clavulanate acid). The
pregnant woman died 5 days after discharge; all pedia-
tric cases died at hospital. The 2 month-old child’s
mother could not be found to assess the potential routes
of transmission. The median time from hospital admis-
sion to death was 3 days (range 1 - 61 days). Fatality
was significantly higher in severe cases (100% (11/11) vs.
46.4% (13/28); p < 0.01). There were no differences in
fatality or severity between acute and chronic cases.
Positive blood culture (21/24 (87.5%) vs. 3/15 (20%); p <
0.01) and none active drug prescribed (23/26 (88.5%) vs.
1/13 (7.7%); p < 0.001) were also significantly associated
with a higher fatality.
Follow-up visits
Of the 28 patients who were discharged, 24 could be
located and visited; only 11 (45.8%) remained alive. Of
these 11, 8 (72.7%) attended follow-up consultations as
recommended. Nine received a treatment with at least 2
active antibiotics after hospital discharge, of which seven
interrupted antibiotics treatment complaining about the
side effects or lack of money. Nevertheless all improved
and were considered as cured during the second follow-
up visit (median 567 days after discharge, range 420 -
1028). Chest X-rays were done at the time of the second
visit in 9 patients who were initially admitted with
radiographic evidence of pneumonia or pleural effusions.
The results showed radiographic recovery (normal chest
X-ray) in four patients while the remaining five had
radiographic imaging of lung sequelae.
Costs
The mean reported cost of the disease was 2,261,378
Riels (US$565; range $25-$5000) including hospital
costs, treatment costs and other related costs, such as
food or transportation. Almost two thirds of the patients
(61.5%, n = 24/39) had to incur debt (range US$150-
1000); a third (28.2%, n = 11/39) sold a cow, buffalo, pig
or poultries and a quarter (25.6%, n = 10/39) other
belongings (gold or land).
Discussion
This report describes patients with pulmonary melioido-
sis, detected through surveillance of ALRI. To our
knowledge, this is the first report of pulmonary melioi-
dosis cases that were followed several months after hos-
pital discharge in Cambodia [12-14].
Fatality rates (~62%) in our cohort were high com-
pared to that of Thailand (40.5% in 2006) [2,16]. These
high rates likely were related to multiple factors,
including inadequate antibiotic therapy, low awareness
of the disease and limited access to health care services
rather than a severity of the disease that is peculiar to
Cambodia.
Indeed, awareness of melioidosis among health profes-
sionals remains low. In the context of high TB endemi-
city and low microbiological capacity in public hospitals,
misdiagnosis of melioidosis taken as TB may not be
uncommon [13]. All the more when six patients’ chest
X-rays were interpreted as TB-like infection by our clin-
ical experts. In the surveillance study, many clinicians
did not account for melioidosis in their first line antibio-
tic treatment when diagnosing severe pneumonia. More-
over, many patients were discharged before having
received bacteriological results; it is recognized in Cam-
bodia that many patients’ families would rather go back
home if they cannot afford to stay longer at the hospital
or when patients are severely ill with little hope of cure.
The turning point in the treatment of bacteremic
melioidosis was the use of ceftazidime reducing by half
fatality [1,17]. Parenteral co-amoxiclav would have been
a cheaper alternative in our study hospital; unfortu-
nately, both drugs are costly and not available in the
National Essential Drugs list. With a potentially high
burden of melioidosis in Cambodia (12 - 14), one should
consider making ceftazidime available by using a generic
form that is now manufactured in Thailand (http://
www.drugs.com/international/cef-4.html). Notably, oral
treatment can still rely on cotrimoxazole - a cheap and
available drug - as susceptibility testing for this antibio-
tic using E-test method has demonstrated no resistance
of B. pseudomallei isolates. This finding contrasts with
that of Northern Thailand where susceptibility of iso-
lates was lower at 87% [18].
The present study showed that melioidosis had a sub-
stantial financial impact on households in rural Cambo-
dia. To pay for these costs, two-thirds of households
had to borrow money and 25% had to sell assets or use
their savings, a finding that is consistent with studies on
cost-of-illness for other infectious diseases in Cambodia
[19]. To put in perspective, the average cost of melioido-
sis was similar to the Gross National Income per capita
in Cambodia, i.e. US$600 in 2008 [20]. These costs were
overwhelming when compared to an average one-week
expenditure on food of US$ 9.5 per household [19].
Previous series reported 37 to 60% of diabetes mellitus
in patients with melioidosis [5]. Only one study has
documented a high prevalence of diabetes mellitus
(~61%) in the sub-group of pulmonary melioidosis [16].
Our results were consistent with that of studies which
reported higher prevalence of diabetes mellitus in bac-
teremic patients [21-23]. However, the proportion of
diabetes mellitus in our series appeared low. This is sur-
prising as the prevalence of diabetes mellitus in
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the population in Kampong Cham province [24]. Simi-
larly, we observed that severe patients were less likely to
have co-morbidities. Diabetes mellitus may have been
under-reported among our patients. Since most of these
patients died quickly after their admission, it is possible
that clinicians were less demanding when interrogating
the family on diabetes as an underlying condition.
Our study has additional limitations. Estimating the
extent of melioidosis and its severity in ALRI is
Figure 1 Chest radiographs evoking tuberculosis in 5 patients with pulmonary melioidosis. A: 48 year-old male; B: 52 year-old male; C: 52
year-old male who had a positive smear for acid-fast bacilli; D, 36 year-old male; E, 43 year-old male
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biological diagnoses. Few of our patients were children
in whom sputum was difficult to collect and therefore
hardly available. However, it is very likely that fewer
children suffer from pulmonary melioidosis [5,12]. In
Thailand, higher incidence rates were found in 40-60
year old adults [21]. In addition, blood culture is rarely
positive in children since they suffer from less severe
forms of melioidosis [5]. Of note, one patient was 2
months old at the time of diagnosis suggesting possible
vertical transmission from mother to child or a neonatal
infection [25]. Unfortunately, we could not trace this
child for the follow-up investigation. Two of the three
children died and were co-infected by H3N2 influenza
virus. It is difficult indeed to relate the severity of the
disease to influenza infection, although reactivation of
melioidosis following influenza infection has been
described in adults [26].
Second, the surveillance study is limited to hospita-
lized cases of pulmonary infection and so does not
include sub-acute forms and other presentations of the
disease; the follow-up questionnaire revealed that one
third of the patients actually had chronic melioidosis
which resulted in overestimating the proportion of
melioidosis in severe acute respiratory infections. Never-
theless, we believe that our series is reasonably represen-
tative of people in the provinces as our hospitals were
the only reference hospitals for their respective
provinces.
Conclusions
We suggest, therefore, that pulmonary melioidosis
should be considered in every patient with TB-like
chest X-rays and negative AFB smears in Cambodia.
The study was able to highlight difficulties faced by
Cambodian clinicians when managing and treating
melioidosis cases. In addition, it is imperative that Cam-
bodian health professionals understand melioidosis and
consider the disease in their differential diagnoses, espe-
cially for pulmonary tuberculosis and almost all other
febrile infections, particularly during the rainy season.
In the meantime, detecting B. pseudomallei in an ende-
mic area could actually be implemented with the use of
throat swabs. This method with 100% specificity (but
low sensitivity, 36%) could be easily disseminated to
Cambodian hospitals [27]. Furthermore, strengthening
hospital laboratories throughout Cambodia with an
easy-to-make Ashdown’s culture medium could be
easily implemented [28]. These two recommendations
taken together would provide further information on
the burden of melioidosis in the different provinces in
Cambodia and subsequently help advocate for the adop-
tion of a national treatment protocol including
ceftazidime.
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